Arcellx, Inc. (ACLX)
ACLX Stock Price Chart
Explore Arcellx, Inc. interactive price chart. Choose custom timeframes to analyze ACLX price movements and trends.
ACLX Company Profile
Discover essential business fundamentals and corporate details for Arcellx, Inc. (ACLX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Feb 2022
Employees
163.00
Website
https://arcellx.comCEO
Rami Elghandour
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
ACLX Financial Timeline
Browse a chronological timeline of Arcellx, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 17 Mar 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$1.00, while revenue estimate is $11.24M.
Earnings released on 7 Aug 2025
EPS came in at -$0.94 surpassing the estimated -$1.03 by +8.74%, while revenue for the quarter reached $7.55M , missing expectations by -44.90%.
Earnings released on 8 May 2025
EPS came in at -$1.13 falling short of the estimated -$0.84 by -34.52%, while revenue for the quarter reached $8.13M , missing expectations by -36.84%.
Earnings released on 27 Feb 2025
EPS came in at -$0.87 falling short of the estimated -$0.63 by -38.10%, while revenue for the quarter reached $15.27M , missing expectations by -40.63%.
Earnings released on 7 Nov 2024
EPS came in at -$0.48 surpassing the estimated -$0.54 by +11.11%, while revenue for the quarter reached $26.03M , missing expectations by -32.78%.
Earnings released on 8 Aug 2024
EPS came in at -$0.51 surpassing the estimated -$0.54 by +5.56%, while revenue for the quarter reached $27.38M , beating expectations by +24.27%.
Earnings released on 9 May 2024
EPS came in at -$0.14 surpassing the estimated -$0.51 by +72.55%, while revenue for the quarter reached $39.26M , beating expectations by +89.96%.
Earnings released on 28 Feb 2024
EPS came in at $0.42 surpassing the estimated -$0.61 by +168.85%, while revenue for the quarter reached $63.15M , beating expectations by +214.71%.
Earnings released on 13 Nov 2023
EPS came in at -$0.81 falling short of the estimated -$0.56 by -44.64%, while revenue for the quarter reached $14.96M , missing expectations by -14.50%.
Earnings released on 14 Aug 2023
EPS came in at -$0.50 surpassing the estimated -$0.68 by +26.47%, while revenue for the quarter reached $14.30M , missing expectations by -63.60%.
Earnings released on 8 May 2023
EPS came in at -$0.58 falling short of the estimated $2.52 by -123.02%, while revenue for the quarter reached $17.91M , missing expectations by -82.26%.
Earnings released on 29 Mar 2023
EPS came in at -$0.76 falling short of the estimated -$0.71 by -7.04%.
Earnings released on 14 Nov 2022
EPS came in at -$0.68 surpassing the estimated -$0.93 by +26.88%.
Earnings released on 15 Aug 2022
EPS came in at -$0.88 surpassing the estimated -$1.20 by +26.67%.
Earnings released on 12 May 2022
EPS came in at -$1.56 falling short of the estimated -$0.95 by -64.21%.
Earnings released on 7 Feb 2022
EPS came in at -$0.62 surpassing the estimated -$0.66 by +6.63%.
Earnings released on 14 Jan 2022
EPS came in at -$0.78 .
Earnings released on 30 Jun 2021
EPS came in at -$0.73 .
Earnings released on 31 Mar 2021
EPS came in at -$0.52 .
Earnings released on 31 Dec 2020
EPS came in at -$0.42 .
ACLX Stock Performance
Access detailed ACLX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.